Quantitative expression proteomics and phosphoproteomics profile of brain from PINK1 knockout mice: insights into mechanisms of familial Parkinson's disease. (1st March 2015)

• Record Type: Journal Article
• Authors: Triplett, Judy C.; Zhang, Zhaoshu; Sultana, Rukhsana; Cai, Jian; Klein, Jon B.; Büeler, Hansruedi; Butterfield, David Allan
• Is Part Of: Journal of neurochemistry. Volume 133:Number 5(2015:Jun.)
• Page Start: 750
• Page End: 765
• Publication Date: 2015-03-01
• Subjects: expression proteomics -- knockout mouse -- Parkinson's disease -- phosphoproteomics -- PINK1; Neurochemistry -- Periodicals; 616.8042
• DOI: 10.1111/jnc.13039
• Languages: English
• ISSNs: 0022-3042

Abstract

Abstract: Parkinson's disease (PD) is an age‐related, neurodegenerative motor disorder characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta and presence of α‐synuclein‐containing protein aggregates. Mutations in the mitochondrial Ser/Thr kinase PTEN‐induced kinase 1 ( PINK1 ) are associated with an autosomal recessive familial form of early‐onset PD. Recent studies have suggested that PINK1 plays important neuroprotective roles against mitochondrial dysfunction by phosphorylating and recruiting Parkin, a cytosolic E3 ubiquitin ligase, to facilitate elimination of damaged mitochondria via autophagy‐lysosomal pathways. Loss of PINK1 in cells and animals leads to various mitochondrial impairments and oxidative stress, culminating in dopaminergic neuronal death in humans. Using a 2‐D polyacrylamide gel electrophoresis proteomics approach, the differences in expressed brain proteome and phosphoproteome between 6‐month‐old PINK1‐deficient mice and wild‐type mice were identified. The observed changes in the brain proteome and phosphoproteome of mice lacking PINK1 suggest that defects in signaling networks, energy metabolism, cellular proteostasis, and neuronal structure and plasticity are involved in the pathogenesis of familial PD. Mutations in PINK1 are associated with an early‐onset form of Parkinson's disease (PD). This study examines changes in the proteome and phosphoproteome of the PINK1 knockout mouse brain. Alterations were noted in several key proteins associated with: increased oxidative stress, aberrant cellular signaling, altered neuronal structure, decreased synaptic plasticity, reduced neurotransmission, diminished proteostasis networks, and altered metabolism. 14‐3‐3ε, 14‐3‐3 protein epsilon; 3‐PGDH, phosphoglycerate dehydrogenase; ALDOA, aldolase A; APT1, acyl‐protein thioesterase 1; CaM, calmodulin; CBR3, carbonyl reductase [NADPH] 3; ENO2, gamma‐enolase; HPRT, hypoxanthine‐guanine phosphoribosyltransferase; HSP70, heat‐shock‐related 70 kDa protein 2; IDHc, cytoplasmic isocitrate dehydrogenase [NADP+]; MAPK1, mitogen‐activated protein kinase 1; MEK1, MAP kinase kinase 1; MDHc, cytoplasmic malate dehydrogenase; NFM, neurofilament medium polypeptide; NSF, N ‐ethylmaleimide‐sensitive fusion protein; PHB, prohibitin; PINK1, PTEN‐induced putative kinase 1; PPIaseA, peptidyl‐prolyl cis‐trans isomerase A; PSA2, proteasome subunit alpha type‐2; TK, transketolase; VDAC‐2, voltage‐dependent anion‐selective channel protein 2. Abstract : Mutations in PINK1 are associated with an early‐onset form of Parkinson's disease (PD). This study examines changes in the proteome and phosphoproteome of the PINK1 knockout mouse brain. Alterations were noted in several key proteins associated with: increased oxidative stress, aberrant cellular signaling, altered neuronal structure, decreased synaptic plasticity, reduced neurotransmission, diminished proteostasis networks, and altered metabolism. 14‐3‐3ε, 14‐3‐3 protein epsilon; 3‐PGDH, phosphoglycerate dehydrogenase; ALDOA, aldolase A; APT1, acyl‐protein thioesterase 1; CaM, calmodulin; CBR3, carbonyl reductase [NADPH] 3; ENO2, gamma‐enolase; HPRT, hypoxanthine‐guanine phosphoribosyltransferase; HSP70, heat‐shock‐related 70 kDa protein 2; IDHc, cytoplasmic isocitrate dehydrogenase [NADP+]; MAPK1, mitogen‐activated protein kinase 1; MEK1, MAP kinase kinase 1; MDHc, cytoplasmic malate dehydrogenase; NFM, neurofilament medium polypeptide; NSF, N ‐ethylmaleimide‐sensitive fusion protein; PHB, prohibitin; PINK1, PTEN‐induced putative kinase 1; PPIaseA, peptidyl‐prolyl cis‐trans isomerase A; PSA2, proteasome subunit alpha type‐2; TK, transketolase; VDAC‐2, voltage‐dependent anion‐selective channel protein 2. This article is related to a companion paper: doi:10.1111/jnc.13037 .